Stricture-free survival
FIGURE 2 · Panel Stricture-free_survival
Panel Stricture-free_survival 是同一 FIGURE 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Masaki Tanaka, Hiroyuki Ono, Kohei Takizawa, Shintaro Iwamoto, Yusuke Sano, Seiichiro Abe, Tomohiro Kadota, Takuya Wada, Akiyoshi Ishiyama, Hiroyoshi Nakanishi, Shinji Nagata, Haruhiko Fukuda, Manabu Muto, Tomonori Yano, Gastrointestinal Endoscopy Study Group of the Japan Clinical Oncology Group
Dig Endosc 38(6) e70195
OBJECTIVES: Endoscopic local triamcinolone injection is a standard therapy for esophageal stricture (ES) prevention after extensive endoscopic submucosal dissection (ESD); however, oral prednisolone administration is a promising alternative. This trial aimed to investigate the superiority of oral prednisolone administration to local triamcinolone injection for ES prevention after extensive ESD. METHODS: This phase 3, open-label, multicenter, randomized controlled trial enrolled patients with extensive superficial esophageal squamous cell carcinoma. The primary endpoint was stricture-free survival (SFS). Secondary endpoints were the number of endoscopic balloon dilations (EBDs) for 12 weeks after ESD, dysphagia score ≤ 1 at 12 weeks after ESD, and adverse events (AEs). RESULTS: A total of 281 patients from 45 institutions were enrolled. The 12-week SFS rates were 88.5% (95% confidence interval [CI]: 81.6-92.9) and 94.8% (95% CI: 89.4-97.5) in the triamcinolone and prednisolone arms, respectively (hazard ratio 0.672, 90% CI [0.361-1.250], p = 0.14). Thirty-eight and 26 EBDs were performed for 14 and 10 patients, respectively, in the triamcinolone and prednisolone arms within 12 weeks after ESD. In the triamcinolone and prednisolone arms, 73.8% (95% CI: 65.7-80.8) and 80.7% (95% CI: 73.2-86.9) of patients, respectively, had dysphagia scores ≤ 1 at 12 weeks after ESD (p = 0.20). Grade 3/4 AEs occurred in 12 (8.7%) and 9 patients (6.7%) in the triamcinolone and prednisolone arms, respectively. CONCLUSIONS: While oral prednisolone administration and local triamcinolone injection demonstrated comparable outcomes, oral prednisolone did not demonstrate superiority for ES prevention after extensive esophageal ESD.
2 个 Figure · 4 个 KM 面板
Stricture‐free survival of both treatment arms. The Stricture‐free survival (SFS) at 12 weeks was 88.5% (95% CI: 81.6–92.9) and 94.8% (95% CI: 89.4–97.5) in the local triamcinolone arm and oral prednisolone arm, respectively (HR 0.67, 90% CI [0.361–1.250], 95% CI [0.321–1.408]; one‐sided p = 0.1442).
FIGURE 2 · Panel Stricture-free_survival
Panel Stricture-free_survival 是同一 FIGURE 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
(a) Stricture‐free survival (SFS) for lesions with luminal circumference of ≥ 3/4 and < 7/8. The 12‐week SFS of the cases with mucosal defect over three‐fourths to seven‐eighths of the lumen was 96.0% (95% CI: 84.9–99.0) and 96.5% (95% CI: 86.7–99.1) in the local triamcinolone arm and the oral prednisolone arm, respectively (HR 1.229, 95% CI [0.275–5.492]). (b) SFS for the lesions with luminal circumference of > 7/8 but not the whole circumference. The SFS at 12 weeks was 75.2% (95% CI: 58.8–85.8) and 92.5% (95% CI: 78.5–97.5) in the local triamcinolone arm and the oral prednisolone arm, respectively (HR 0.545, 95% CI [0.198–1.502]). (c) SFS for the lesions with a whole‐circumference mucosal defect. The SFS at 12 weeks was 50.0% (95% CI: 11.1–80.4) and 75.0% (95% CI: 12.8–96.1) in the local triamcinolone arm and the oral prednisolone arm, respectively (HR 0.360, 95% CI [0.040–3.223]).
FIGURE 3 · Panel A
Panel A 是同一 FIGURE 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIGURE 3 · Panel B
Panel B 是同一 FIGURE 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIGURE 3 · Panel C
Panel C 是同一 FIGURE 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。